Fluxergy Acquires Employees, Assets and Licenses Technology from InnaMed, Inc
Fluxergy Announces the Acquisition of Certain Employees and Assets and the License of Electrochemical Biosensing Technology from InnaMed, Inc.
IRVINE, Calif., March 2, 2023 /PRNewswire-PRWeb/ -- Fluxergy, a medical diagnostic company focused on multiplex, multimodal point-of-care (POC) testing, announced today that it has acquired certain employees and assets and licensed electrochemical biosensing technology from InnaMed, Inc., a Y Combinator-backed biotechnology company.
InnaMed built a platform for decentralized blood testing through electrochemical biosensor technology with the HomeLab™ device and analysis software. The license of this technology will further expand the Fluxergy platform's microfluidic portfolio with the incorporation of InnaMed's electrochemical technology. Currently, the Fluxergy Analyzer utilizes four major sensor and fluidics systems: fluorescence, colorimetry, electrical potentiometry, and imaging cytometry. This allows for seamless integration of InnaMed's core technology into the architecture of the Fluxergy Analyzer, Test Card, and the Fluxergy Works software platform.
InnaMed's technology supports Fluxergy's goal of developing a rapid basic metabolic panel (BMP). Common biomarkers like glucose, electrolytes, hormones, liver proteins, and cardiac proteins are detectable using electrochemical sensing. This presents new opportunities for assay developers using the Fluxergy's open platform model, a system which allows partners to integrate custom assays onto Fluxergy's POC platform while utilizing their scalable manufacturing facilities.
"Fluxergy envisions giving clinicians, healthcare providers, and laboratory professionals access to as many basic and specialized laboratory tests as possible from a single, decentralized platform; that is why we continue to grow our technological capabilities and detection modalities," said Fluxergy President Tej Patel. "We are also excited to bring on key members of InnaMed's talented team as consultants, in addition to its innovative technology, to continue pushing the boundaries of point-of-care."
With the addition of the new technologies, Fluxergy plans to expand its detection capabilities to small molecule and clinical chemistries in human health, equine and small animal veterinary medicine, and other industries that can benefit from cost-effective analyte detection.
About Fluxergy
Fluxergy is a medical device manufacturing company specializing in point-of-use detection technologies with the goal of making affordable diagnostics accessible in all settings. The Fluxergy Analyzer platform combines the capabilities of many machines into one multimodal system, delivering more affordable laboratory-quality test results and actionable metrics in 60 minutes or less. The core of this system is a highly scalable microfluidic test card which allows for the combined detection of proteins, nucleic acids, small molecules, and cells. Fluxergy's current test offerings include COVID-19, a human respiratory panel (COVID-19/FluA+B/RSV), Equine EHV-1, and Environmental Salmonella, with thirteen other assays in development.
For more information, contact:
Eric Mendonsa, Director of Business Development
+1 (949) 305-4201 ext. 507
[email protected]
###
Media Contact
Harry Penn, Fluxergy, 1 (949) 305-4201 Ext: 827, [email protected]
SOURCE Fluxergy
Share this article